Chemistry characterization and antioxidant activity of mangosteen (Garcinia mangostana L, Clusiaceae) cultivated in Colombia / Caracterización química y actividad antioxidante del mangostino (Garcinia mangostana L, Clusiaceae) cultivado en Colombia

The objective of this work was to evaluate the antioxidant and inhibitory activities of the ethanolic extracts of the mangosteen (Garcinia mangostana L.) grown in Montenegro, Quindío, Colombia, in three stages of maturation, including the edible (pulp) and inedible parts (pericarp and peduncle). The alcoholic samples were phytochemically characterized by Thin Layer Chromatography (TLC), High Performance Liquid Chromatography (HPLC) and by Fourier Transformation Infrared Spectroscopy (FT-IR); the antioxidant capacities were also evaluated by the diphenyl-picrylhydrazyl (DPPH•) radical method and Oxygen Radical Absorbance Capacity (ORAC), in addition to the inhibitory activity of acetylcholinesterase (AchE) and the total content of phenols and flavonoids. The tests detected phytochemical compounds such as phenols, flavonoids, alkaloids, quinones and xanthones, to which the antioxidant activity and the inhibition of AChE presented, can be attributed. In conclusion, the inedible parts of mangosteen contain higher proportions of secondary metabolites, these being the most promising sources for industrial use.

El objetivo de este trabajo fue el de evaluar las actividades antioxidantes e inhibitoria de acetilcolinesterasa de los extractos etanólicos del mangostino (Garcinia mangostana L.) de Montenegro, Quíndio, Colombia, en tres estados de maduración, incluyendo las partes comestibles (pulpa) y no comestibles (pericarpio y pedúnculo). Las muestras alcohólicas fueron caracterizadas fitoquímicamente por Cromatografía de Capa Delgada (CCD), Cromatografía Líquida de Alta Eficiencia (HPLC) y Espectroscopía Infrarroja por Transformada de Fourier (FT-IR); la capacidad antioxidante fue evaluada también por el método de captación del radical libre 2,2-difenil-1-picrilhidracilo (DPPH• dejar el radical en superíndice) y la Capacidad de Absorción de Radicales de Oxígeno (ORAC), adicionalmente la actividad inhibitoria de la acetilcolinesterasa (AchE) y el contenido total de fenoles y flavonoides. Se detectaron compuestos fitoquímicos como fenoles, flavonoides, alcaloides, quinonas y xantonas, a quienes se les puede atribuir las actividades antioxidantes y de inhibición de la acetilcolinesterasa. En conclusión, las partes no comestibles del mangostino contienen una mayor proporción de metabolitos secundarios, siendo las fuentes más promisorias para uso industrial.

Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.

The safety and efficacy of drug substances or products do not solely depend on its active(s). The quantity of impurities present in the product has a significant role in its safety profile. Pharmaceutical impurities are one of the primary reasons for the withdrawal of many approved products from the market. Therefore, the level of impurities in the pharmaceuticals needs to be controlled within a specified safe limit. Nowadays, setting impurity level specification remains a great challenge for pharmaceutical manufacturers. Regulatory guidelines recommend to control the impurity based on the concentration level criteria and provides limits of allowable impurities in pharmaceuticals. However, a single set of impurity limits cannot work for all the drug substances. There are numerous reasons which demand to set the impurity level specification based on safety dominated critical quality attribute principle. In this review, we have discussed the need for the consideration of both concentration based and patient safety-related approaches for setting the impurity level specification. To achieve this goal, it is required to identify the safety limits of the impurities during clinical development and provide a specification for the finished pharmaceutical products before entering the market. However, tremendous challenges faced by pharmaceutical companies to have an appropriate balance amongst the critical factors like safety, efficacy, analytical variability, process knowledge and regulatory requirement. Finally, the specification for API and finished drug product should be established considering both quality and patient safety. Considering all such factors, we have included a systematic and scientific approach that can guide to establish the safe and flexible impurity limit specification for pharmaceuticals.